Browse the evidence

The health benefits of non-occupational physical activity follow a non-linear dose-response curve, where the greatest risk reduction occurs between 0 and 8.75 mMET-hours/week, with diminishing returns above 17.5 mMET-hours/week.

You get the most 'bang for your buck' by moving from a sedentary lifestyle to a moderately active one (150 mins/week). Doing more than double that amount (300 mins/week) offers smaller additional health benefits, so prioritize consistency over intensity if you are busy.

Weight loss of 5-10% significantly improves reproductive outcomes (ovulation, menstrual regularity) and metabolic markers (insulin resistance, lipids) in women with PCOS, regardless of the specific dietary composition used to achieve the weight loss.

Aim for a 5-10% reduction in body weight through a moderate energy deficit (500-750 kcal/day). You do not need to follow a specific restrictive diet (like low-carb or low-fat) to see benefits; any dietary approach that helps you achieve this weight loss will improve insulin resistance, lipids, and reproductive health.

Adherence to a Mediterranean Diet reduces the risk of developing Type 2 Diabetes by 19-30% and improves glycemic control (HbA1c) in existing patients.

Adhere to a Mediterranean Diet to significantly lower your risk of developing Type 2 Diabetes. This dietary pattern is recommended by major diabetes associations for improving glucose and lipid metabolism.

Adherence to a Mediterranean Diet improves cardiovascular risk factors (lipids, blood pressure) and reduces the risk of cardiovascular disease events in patients with Type 2 Diabetes.

If you have Type 2 Diabetes, following a Mediterranean Diet can significantly improve your blood sugar, cholesterol, and blood pressure levels, reducing your risk of heart disease and stroke.

Semaglutide 2.4 mg once weekly improves symptoms, exercise capacity, and reduces inflammation in patients with obesity-phenotype heart failure with preserved ejection fraction (HFpEF) across all obesity classes (BMI 30-34.9, 35-39.9, and ≥40 kg/m²), with clinical benefits directly proportional to the magnitude of weight loss.

If you have heart failure with preserved ejection fraction and obesity, semaglutide (2.4 mg weekly) is a proven treatment that improves your heart symptoms, exercise ability, and inflammation. The more weight you lose, the more you benefit, regardless of whether your obesity is Class I, II, or III. This treatment works best when combined with a moderate caloric deficit (500 kcal/day) and regular physical activity.

Functional and balance training performed at least twice weekly significantly reduces the rate of falls in adults over 50, with high-certainty evidence supporting this intervention for fracture prevention.

Perform balance and functional exercises at least twice a week. Focus on activities that challenge your stability, such as standing on one foot, heel raises, or agility drills. Progressively make these exercises harder by increasing speed, complexity, or resistance. This is the most effective non-pharmacological way to prevent falls in older adults.

Pharmacotherapy is recommended for postmenopausal females and males aged 50+ who have had a previous hip or vertebral fracture, or have a 10-year major osteoporotic fracture risk of 20% or more.

If you are over 50 and have had a hip or vertebral fracture, or have a high 10-year fracture risk (20% or more), you should strongly consider pharmacotherapy. This is a strong recommendation based on high-certainty evidence. Your doctor will help you choose the right medication based on your specific risks and preferences.

Consumption of yoghurt and fermented milk products is associated with reduced cardiovascular disease risk factors, including lower total cholesterol, LDL cholesterol, triglycerides, and blood pressure.

Include yoghurt or fermented milk in your diet to support heart health. High intake is linked to lower cardiovascular mortality and improved cholesterol profiles. Whole-fat yoghurt may offer metabolic benefits comparable to or better than low-fat options.

Increasing dietary fiber intake significantly reduces systolic and diastolic blood pressure in adults with hypertension, regardless of concurrent antihypertensive medication use.

If you have high blood pressure, increasing your daily fiber intake by about 6-12 grams (e.g., adding more beans, oats, or vegetables) can significantly lower your blood pressure. This benefit holds true even if you are already taking blood pressure medication, making it a powerful addition to your current treatment plan.

Macronutrient composition (low-carb vs. low-fat) has no significant difference on weight loss outcomes when total caloric intake and adherence are controlled.

Don't obsess over whether you should be low-carb or low-fat. The most important factor is that you eat fewer calories than you burn. You can achieve this with almost any dietary pattern (Mediterranean, low-carb, low-fat) as long as you stick to it and maintain a calorie deficit.

Liraglutide (3.0 mg daily) is effective for weight loss but significantly less so than Semaglutide, with a mean weight loss of 6.4% compared to 15.8%.

Liraglutide (3.0 mg daily) is an FDA-approved option for weight loss, but it produces roughly half the weight loss of Semaglutide (6.4% vs 15.8%). It requires daily injections, which may be burdensome, and you must reach the 3.0 mg dose to see full effects. If you cannot tolerate Semaglutide, this is a viable alternative, but expect less dramatic results.

Certain anti-diabetic medications, specifically insulin, can increase body weight, creating a conflict in treating obesity and T2DM simultaneously.

If you are prescribed insulin for diabetes, be aware it can cause weight gain. Discuss weight-neutral or weight-loss promoting alternatives (like GLP-1 agonists or SGLT2 inhibitors, though not explicitly named here, implied by 'anti-obesity drugs') with your doctor if weight management is a priority.

Once-weekly semaglutide (2.4 mg) significantly improves heart failure symptoms, physical limitations, and exercise capacity in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes, independent of the magnitude of weight loss.

If you have heart failure with preserved ejection fraction, are obese, and have type 2 diabetes, once-weekly semaglutide (2.4 mg) can significantly reduce your heart failure symptoms and help you lose weight. This treatment works even if your weight loss isn't as dramatic as in people without diabetes, suggesting it helps your heart directly. It is administered as a weekly injection, starting at a low dose to minimize side effects, and titrated up over 16 weeks.

The proportion of T2D attributable to diet is inversely correlated with age, being highest in younger adults (83.5% for ages 20-25) and lowest in older adults (27.7% for ages 95+).

Start eating well early in life. The proportion of diabetes cases driven by diet is highest in young adults, meaning early dietary habits have a massive impact on lifetime risk.

Genetically elevated body mass index (BMI) causally increases the risk of 316 distinct clinical diagnoses across circulatory, metabolic, respiratory, and genitourinary systems, with risk burden increasing significantly as BMI categories rise.

Your body weight is not just a cosmetic issue; it is a causal driver for hundreds of health conditions, including heart failure, diabetes, and sleep apnea. The risk increases as your BMI rises. Managing your weight through diet and activity is one of the most effective ways to reduce your risk for these specific, serious diseases, regardless of your genetic background.

GLP-1 receptor agonists delay gastric emptying, which reduces postprandial lipid and carbohydrate surges and contributes to satiety.

GLP-1 medications slow down how fast food leaves your stomach. This helps you feel full longer and prevents sharp spikes in blood sugar after meals.

GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACE), death, and stroke in patients with type 2 diabetes.

If you have type 2 diabetes, GLP-1 receptor agonists can significantly lower your risk of heart attacks, strokes, and death. This benefit is independent of weight loss and is supported by large-scale data involving over 60,000 patients.

High body weight (obesity) causes increased psychological distress and depressive symptoms, primarily through weight stigma and biological mechanisms like HPA-axis dysregulation and systemic inflammation.

If you have obesity, be aware that societal stigma and biological factors like inflammation can contribute to depression. Focus on mental health support and reducing stigma rather than self-blame. Healthcare providers should adopt weight-inclusive attitudes to improve patient wellbeing.

Once-weekly subcutaneous semaglutide (2.4 mg) significantly alters the circulating proteome in individuals with obesity, downregulating proteins associated with cardiovascular disease risk and inflammatory pathways beyond what is explained by weight loss and glycemic control alone.

If you have obesity and are considering semaglutide, know that it does more than just help you lose weight. It actively changes your blood proteins to lower your risk of heart disease and inflammation, even independent of the weight you lose. This makes it a valuable tool for cardiovascular protection in high-risk individuals, not just a weight-loss aid. The benefits are supported by large, rigorous clinical trials.

Tirzepatide 15mg is associated with a higher rate of adverse events compared to other GLP-1RAs, although not significantly different from placebo in some metrics, it ranks highest in SUCRA for adverse events.

Tirzepatide 15mg is highly effective but comes with a higher risk of side effects like nausea and diarrhea compared to other GLP-1s. Patients should be prepared for this and work with their doctor on dose titration to manage it.

GLP-1 receptor agonists reduce the risk of Major Adverse Cardiovascular Events (MACE) by 13-26% in patients with type 2 diabetes and high cardiovascular risk.

If you have type 2 diabetes and heart disease or high heart risk, GLP-1 medications like semaglutide or liraglutide are recommended not just for blood sugar, but to protect your heart. Studies show they can lower the risk of heart attacks and strokes by 13-26% compared to placebo.

GLP-1 receptor agonists improve cardiovascular outcomes by reducing major adverse cardiovascular events (MACE), including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke, in patients with type 2 diabetes and established cardiovascular disease.

If you have type 2 diabetes and existing heart disease, certain GLP-1 medications (like liraglutide, semaglutide, or dulaglutide) can significantly lower your risk of heart attack, stroke, or cardiovascular death. This benefit is independent of weight loss and is a key reason these drugs are recommended for high-risk patients.

Discontinuation of semaglutide treatment leads to significant weight regain, resulting in net weight loss that is substantially lower than the peak loss achieved during treatment.

If you stop taking semaglutide, you will likely regain most of the weight you lost. The net weight loss after stopping is much smaller than the peak loss. Long-term maintenance may require continued treatment.

GLP-1 receptor agonists (Liraglutide, Semaglutide) and Tirzepatide reduce food intake primarily by increasing satiety and reducing neural activation in brain areas associated with appetite and reward, rather than just delaying gastric emptying.

Semaglutide (2.4 mg weekly) works by acting on your brain to make you feel full sooner and reducing the desire for high-calorie foods. It is not just about stomach emptying. Start with a low dose to minimize side effects, titrating up to 2.4 mg over several months.